Expansion of Ibuprofen Capacity, New CDMO Business for Pharmaceutical Formulation and Dedicated Specialty Chemicals Manufacturing Facility
Expansion of Ibuprofen capacity by 6,000 MT to total 18,000 MT per annum at Barnala site; project cost ~₹350 Cr funded by internal accruals. New CDMO pharmaceutical formulation facility with 1,500 million tablets capacity established at Barnala; cost ~₹110 Cr, GMP certified in Hungary, commercialisation expected Q3 FY27. Dedicated specialty chemicals manufacturing facility under long-term tolling for global customer; capex ~₹35 Cr, commercialisation expected Q3 FY27.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 IOLCP — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add IOLCP to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on IOL Chemicals and Pharmaceuticals Limited
Important.
The summary above is generated automatically from IOL Chemicals and Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.